Home > European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) annual report 2005: selected issues.

European Monitoring Centre for Drugs and Drug Addiction. (2005) European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) annual report 2005: selected issues. Luxembourg: Office for Official Publications of the European Communities.

[img]
Preview
PDF (Selected issue 2005 Drug-related public nuisance) - Published Version
214kB
[img]
Preview
PDF (Selected issue 2005 Alternatives to imprisonment) - Published Version
187kB
[img]
Preview
PDF (Selected issue 2005 Buprenorphine) - Published Version
673kB

1. This Selected issue is not intended to present a systematic and exhaustive review either of all possible definitions of drug-related public nuisance or of all measures, provisions and policies aimed at reducing the problem in the European Union, nor does it aim to reflect precisely the situation regarding public nuisance in each of the countries concerned. Rather, it seeks to contribute to our understanding of the issues and problems related to a new – and somewhat still limited – area for intervention in Member States, candidate countries and Norway. This document aims to present the first EMCDDA qualitative insight into an emerging concern within drug policy debate, at both national and European levels.

2. The alternatives to prison that may be offered to drug-using offenders cover a range of sanctions that may delay, avoid, replace or complement prison sentences for those drug users who have committed an offence normally sanctioned with imprisonment by national law. In this Selected issue, the focus is on those measures that have a drug-related treatment component. It will describe the political and legal background, the application and implementation, including common problems, and the effects of treatment as an alternative to imprisonment.

3. Since the mid-1990s buprenorphine has increasingly become available in Europe as an alternative to methadone for the treatment of opiate dependence. In this Selected issue, the reasons why clinicians are attracted to this drug, as well as the costs and benefits of buprenorphine in comparison with other treatment options, are explored in detail, and, for the first time, the increasing popularity of buprenorphine for the treatment of opiate dependence in many European countries is documented


Date:2005
Call No:REF, EMCDDA
Pages:45 p.
Publisher:Office for Official Publications of the European Communities
Corporate Creators:European Monitoring Centre for Drugs and Drug Addiction
Place of Publication:Luxembourg
ISBN:92-9168-246-2
EndNote:View
Accession Number:HRB 4439 (Available)
Related URLs:
Subjects:B Drugs and alcohol substances > Opioids (opiates) > Opioid product > Buprenorphine / Suboxone
MM-MO Crime and law > Crime > Drugs and alcohol related crime
MM-MO Crime and law > Justice system
R Research > Type of research study > Research involving two or more groups > Cross-cultural study
VA Geographic area > Europe > European Union

Repository Staff Only: item control page